Your SlideShare is downloading. ×
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Monoclonal Antibodies Partnering Terms and Agreements Available on Researchmoz.us

176

Published on

The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered …

The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
176
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. Monoclonal Antibodies Partnering Terms and AgreementsThe Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understandingand unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by theworlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter monoclonalantibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right oran option right to license the licensors monoclonal antibody technology. These deals tend to bemulticomponent, starting with collaborative R&D, and commercialization of outcomes. This report providesdetails of the latest monoclonal antibody deals announced in the healthcare sectors. Understanding theflexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiationprocess in terms of what you can expect to achieve during the negotiation of terms. Whilst many smallercompanies will be seeking details of the payments clauses, the devil is in the detail in terms of how paymentsare triggered – contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of all monoclonal antibody partnering dealsannounced since 2007 including financial terms where available including over 700 links to online dealrecords of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available,records include contract documents as submitted to the Securities Exchange Commission by companies andtheir partners. Contract documents provide the answers to numerous questions about a prospectivepartner’s flexibility on a wide range of important issues, many of which will have a significant impacton each party’s ability to derive value from the deal. For example, analyzing actual company dealsand agreements allows assessment of the following: What is actually granted by the agreement to thepartner company? What exclusivity is granted? What are the precise rights granted or optioned? Whatis the payment structure for the deal? How aresalesand payments audited? What is the deal term? How arethe key terms of the agreement defined? How are IPRs handled and owned? Who is responsible forcommercialization? Who is responsible for development, supply, and manufacture? How is confidentiality andpublication managed? How are disputes to be resolved? Under what conditions can the deal be terminated?What happens when there is a change of ownership? What sublicensing and subcontracting provisions havebeen agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear todiffer from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon foragreement law? The initial chapters of this report provide an orientation of monoclonal antibodydealmaking and business activities.Chapter 1 provides an introduction to the report, whilstChapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2007, includingdetails of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review ofthe leading monoclonal antibody deals since 2007. Deals are listed by headline value and most active of allbiopharma companies. Where the deal has an agreement contract published at the SEC a link provides onlineaccess to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharmacompanies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well ascontract documents available in the public domain. Where available, each deal title links via Weblink to anonline version of the actual contract document, providing easy access to each contract document on demand.Monoclonal Antibodies Partnering Terms and Agreements
  2. Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followedby a comprehensive listing of monoclonal antibody deals as well as contract documents available in the publicdomain. Where available, each deal title links via Weblink to an online version of the actual contractdocument, providing easy access to each contract document on demand. Chapter 6 provides a comprehensiveand detailed review of monoclonal antibody partnering deals signed and announced since January 2007, wherea contract document is available in the public domain. The chapter is organized by stage of development atsigning, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal titlelinks via Weblink to an online version of the deal record, providing easy access to each contract document ondemand. Chapter 7 provides a comprehensive list and detailed review of monoclonal antibody partneringdeals signed and announced since January 2007, by specific technology type. Where available, each deal titlelinks via Weblink to an online version of the actual contract document, providing easy access to each contractdocument on demand. In addition, a comprehensive appendix is provided organized by monoclonal antibodypartnering company A-Z, deal type, stage of development and therapy type deals. Each deal title links viaWeblink to an online version of the deal record and where available, the contract document, providing easyaccess to each contract document on demand. In conclusion, this report provides everything a prospectivedealmaker needs to know about partnering in the research, development and commercialization of biomarkertechnologies and products. Report scope Monoclonal Antibodies Partnering Terms &Agreements is intended to provide the reader with an in-depth understanding and access to monoclonalantibodies trends and structure of deals entered into by leading companies worldwide.Monoclonal Antibodies Partnering Terms & Agreements includes:Trends in monoclonal antibodies dealmaking in the biopharma industry since 2007 Analysis of monoclonalantibodies deal structure Access to headline, upfront, milestone and royalty data Access to over 700monoclonal antibodies deal records The leading monoclonal antibodies deals by value since 2007 Includeschimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2007In Monoclonal Antibodies Partnering Terms & Agreements, the available deals are listed by: CompanyA-Z Headline value Stage of development at signing Deal component type Monoclonal antibodies typeEach deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand. The Monoclonal AntibodiesPartnering Terms & Agreements report provides comprehensive access to available deals and contractdocuments for over 700 monoclonal antibody deals.Analyzing actual contract agreements allows assessment of the following: What are theprecise rights granted or optioned? What is actually granted by the agreement to the partner company? Whatexclusivity is granted? What is the payment structure for the deal? How aresalesand payments audited? Whatis the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who isresponsible for commercialization? Who is responsible for development, supply, and manufacture? How isconfidentiality and publication managed? How are disputes to be resolved? Under what conditions can thedeal be terminated? What happens when there is a change of ownership? What sublicensing andsubcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Whichboilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction doesthe company insist upon for agreement law?table Of ContentMonoclonal Antibodies Partnering Terms and Agreements
  3. executive Summarychapter 1 – Introductionchapter 2 – Trends In Monoclonal Antibody Dealmaking2.1. Introduction2.2. Monoclonal Antibody Partnering Over The Years2.3. Bigpharma Monoclonal Antibody Dealmaking Activity2.4. Big Biotech Monoclonal Antibody Dealmaking Activity2.5. Monoclonal Antibody Partnering By Deal Type2.6. Monoclonal Antibody Partnering By Disease Type2.7. Monoclonal Antibody Partnering By Technology Type2.8 Average Deal Terms For Monoclonal Antibody2.8.1 Monoclonal Antibody Headline Values2.8.2 Monoclonal Antibody Upfront Payments2.8.3 Monoclonal Antibody Milestone Payments2.8.4 Monoclonal Antibody Royalty Rates2.9. The Anatomy Of Monoclonal Antibody Partnering2.9. The Anatomy Of A Monoclonal Antibody Deal2.9.a. Case Study 1: Adma Biologics- Biotest: December 31 20122.9.b. Case Study 2: Case Study 2: Amgen- Astrazeneca: April 2, 2012chapter 3 – Leading Monoclonal Antibody Deals3.1. Introduction3.2. Top Monoclonal Antibody Deals By Value3.3. Top 10 Active Monoclonal Antibodies Dealmakerschapter 4 – Bigpharma Monoclonal Antibody Deals4.1. Introduction4.2. How To Use Bigpharma Monoclonal Antibody Partnering Deals4.3. Big Pharma Monoclonal Antibody Partnering Company Profilesabbottactavis Inc (formerly Watson Pharmaceuticals)amgenastellasastrazenecabayerbiogen Idecboehringer Ingelheimbristol-myers SquibbcelgenecslMonoclonal Antibodies Partnering Terms and Agreements
  4. daiichi Sankyoeisaieli Lillygilead Sciencesglaxosmithklinejohnson & Johnsonkyowa Hakko Kirinlundbeckmenarinimerck & Comerck Kgaamitsubishi Tanabenovartisnovo Nordiskotsukapfizerrochesanofiserviershionogitakedatevaucbchapter 5 –big Biotech Monoclonal Antibodies Deals5.1. Introduction5.2. How To Use Big Biotech Partnering Deals5.3. Big Biotech Monoclonal Antibodies Partnering Company Profilesalexion Pharmaceuticalsamgenbioconbiogen Ideccelgenecslelanemergent Biosolutionsgenmabgilead Sciencesimmunomedicsmorphosyspdl Biopharmaregeneron PharmaceuticalsrocheMonoclonal Antibodies Partnering Terms and Agreements
  5. seattle Geneticsspectrum Pharmaceuticalsucbchapter 6 – Monoclonal Antibody Dealmaking Directory6.1. Introduction6.2. Company A-z3maaipharmaabbott Laboratoriesadma Biologicsagensysalexion Pharmaceuticalsallphase Clinical Research Servicesamgenastellasastrazenecaavanir Pharmaceuticalsavecia Biologicsaventisaveo Pharmaceuticalsbayerbayer Schering Pharmabiogen Idecbiotestboehringer Ingelheimbristol-myers Squibbcancer Research Technologycancervaxcell-matrixcell Therapeuticscelldex Therapeuticscellectiscentocor Ortho Biotechcimab Sacimymcrucellcytodyndaiichi SankyodyaxelanMonoclonal Antibodies Partnering Terms and Agreements
  6. emergent Biosolutionsfacet Biotechnologyge Healthcaregenentechgenzymeglaxosmithklineglycartgtc Biotherapeuticsimmunocellular Therapeuticsimmunogenimmunomedicsintellect Neurosciencesjanssen Pharmaceutica Nvjohnson & Johnsonkalobioslfb Biotechnologieslonzalpathmassachusetts Biologic Laboratoriesmedarexmedimmunemerck And Comerck Seronomerrimack Pharmaceuticalsmicrometmillenniummolecular Discoveriesmrc Technologynational Institute Of Allergy And Infectious Diseasesnovo Nordisknycomedoklahoma Medical Research Foundationoncoscience Agorbimed Advisorsortho-mcneilpdl Biopharmapercipio Biotherapeuticsperegrine Pharmaceuticalspfizerpharmatheneprogenics Pharmaceuticalsregeneron PharmaceuticalsrepligenMonoclonal Antibodies Partnering Terms and Agreements
  7. rit Oncologyrochesanofi-aventissanofi-pasteurschering-ploughseattle Geneticsseronoservierspectrum Pharmaceuticalsstason Pharmaceuticalstakeda Pharmaceuticaltargepeuticstracon Pharmaceuticalsucbuniversity Of Southamptonvista Biologicalswyethxomaym Bioscienceszymogenetics6.3. By Deal Typeasset Purchaseassignmentbigpharma Outlicensingco-developmentcollaborative R&dcontract Serviceco-promotioncross-licensingdevelopmentequity Purchaseevaluationgrantjoint Venturelicensingmanufacturingmarketingoptionpromotionresearchroyalty FinancingsettlementsupplyMonoclonal Antibodies Partnering Terms and Agreements
  8. termination6.4. By Stage Of Developmentdiscoverymarketedphase Iphase Iiphase Iiipreclinicalregulatory6.5. By Therapy Indicationcardiovascularcentral Nervous Systemdermatologygastrointestinalgynaecologyhematologyhospital Careimmunologyinfectivesmetabolicmusculoskeletaloncologyophthalmicspsychiatryrespiratorychapter 7 – Monoclonal Antibody Deals By Individual Technology Typechapter 8 – Monoclonal Antibody Partnering Resource Center8.1. Online Monoclonal Antibody Partnering8.2. Monoclonal Antibody Partnering Events8.3. Further Reading On Monoclonal Antibody Dealmakingabout Wildwood Venturescurrent Partneringcurrent Agreementsrecent Titles From Currentpartneringorder Form – Technology Reportsorder Form – Therapy Reportsorder Form – Deal Type Reportssee Accompanying Volume For:Monoclonal Antibodies Partnering Terms and Agreements
  9. appendicesintroductionappendix 1 – Directory Of Drug Delivery Deals By Company A-z 2007-2012appendix 2 – Directory Of Drug Delivery Deals By Stage Of Development 2007-2012appendix 3 – Directory Of Drug Delivery Deals By Deal Type 2007-2012appendix 4 – Directory Of Drug Delivery Deals By Therapy Area 2007-2012appendix 5 – Drug Delivery Partnering Resource Centeronline Drug Delivery Partneringdrug Delivery Partnering Eventsfurther Reading On Drug Delivery DealmakingResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onwhich reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usWebsite: http://www.researchmoz.us/Monoclonal Antibodies Partnering Terms and Agreements

×